Advances in Renal Cell Carcinoma Drug Resistance Models (Q112053038)

17 May 2022

Ge Zheng

2

1 reference

17 May 2022

Jianfeng Zhong

3

1 reference

17 May 2022

Jiyao Sheng

4

1 reference

17 May 2022

Hanjiao Qin

Creative Commons Attribution 4.0 International

5

1 reference

17 May 2022

10 May 2022

1 reference

17 May 2022

Frontiers in Oncology

1 reference

17 May 2022

12

1 reference

17 May 2022

start time

10 May 2022

1 reference

April 2023 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways

1 December 2023

2 references

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

1 December 2023

https://opencitations.net/index/api/v1/citations/10.2147/DDDT.S343718

Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge?

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Comparative pO2 measurements in cell spheroids cultured with different techniques

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells

1 December 2023

2 references

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

1 December 2023

https://opencitations.net/index/api/v1/citations/10.3390/IJMS22126467

Everolimus resistance in clear cell renal cell carcinoma: miRNA-101 and HIF-2α as molecular triggers?

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Induction of epithelial-mesenchymal transition via activation of epidermal growth factor receptor contributes to sunitinib resistance in human renal cell carcinoma cell lines

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Drug and radiation resistance in spheroids: cell contact and kinetics

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

ALDH1A1 in patient-derived bladder cancer spheroids activates retinoic acid signaling leading to TUBB3 overexpression and tumor progression

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Cellular Adaptation to VEGF-Targeted Antiangiogenic Therapy Induces Evasive Resistance by Overproduction of Alternative Endothelial Cell Growth Factors in Renal Cell Carcinoma.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Potential tumor‑suppressive role of microRNA‑99a‑3p in sunitinib‑resistant renal cell carcinoma cells through the regulation of RRM2

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

The efficacy of cetuximab in a tissue-engineered three-dimensional in vitro model of colorectal cancer

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

CRISPR-mediated ablation of overexpressed EGFR in combination with sunitinib significantly suppresses renal cell carcinoma proliferation

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Drug Repurposing to Identify a Synergistic High-Order Drug Combination to Treat Sunitinib-Resistant Renal Cell Carcinoma

1 December 2023

2 references

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

1 December 2023

https://opencitations.net/index/api/v1/citations/10.3390/CANCERS13163978

CRISPR/Cas9 genome-wide loss-of-function screening identifies druggable cellular factors involved in sunitinib resistance in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Two mutations affecting conserved residues in the Met receptor operate via different mechanisms

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Depletion of lncRNA MALAT1 inhibited sunitinib resistance through regulating miR-362-3p-mediated G3BP1 in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Down-regulation of miR-210-3p encourages chemotherapy resistance of renal cell carcinoma via modulating ABCC1.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Long Non-coding RNA CCAT1 Acts as an Oncogene and Promotes Sunitinib Resistance in Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Wogonin Induces Apoptosis and Reverses Sunitinib Resistance of Renal Cell Carcinoma Cells via Inhibiting CDK4-RB Pathway

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Significance of cyclooxygenase-2, prostaglandin E2 and CD133 levels in sunitinib-resistant renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Size-dependent oxygenation and energy status in multicellular tumor spheroids

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC)

1 December 2023

2 references

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

1 December 2023

https://opencitations.net/index/api/v1/citations/10.3390/CANCERS13174401

Splice variants of lysosome‑associated membrane proteins 2A and 2B are involved in sunitinib resistance in human renal cell carcinoma cells

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Sphingosine kinase 1 overexpression contributes to sunitinib resistance in clear cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Extracellular vesicles transmitted miR-31-5p promotes sorafenib resistance by targeting MLH1 in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Resistance to sunitinib in renal clear cell carcinoma results from sequestration in lysosomes and inhibition of the autophagic flux

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Activating mutations for the met tyrosine kinase receptor in human cancer

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Ovatodiolide Targets β -Catenin Signaling in Suppressing Tumorigenesis and Overcoming Drug Resistance in Renal Cell Carcinoma.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Identification of MicroRNAs Involved in Resistance to Sunitinib in Renal Cell Carcinoma Cells.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

miR-130b Promotes Sunitinib Resistance through Regulation of PTEN in Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

A paper-based invasion assay: assessing chemotaxis of cancer cells in gradients of oxygen

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study)

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

G-Protein-coupled Estrogen Receptor 1 Agonist G-1 Perturbs Sunitinib Resistance-related Phosphoproteomic Signatures in Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Potential new therapy of Rapalink-1, a new generation mTOR inhibitor, against sunitinib-resistant renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

LINC00160 mediates sunitinib resistance in renal cell carcinoma via SAA1 that is implicated in STAT3 activation and compound transportation

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Hydrogels as extracellular matrix mimics for 3D cell culture.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Three-dimensional cell culture: a breakthrough in vivo.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Sunitinib treatment promotes metastasis of drug-resistant renal cell carcinoma via TFE3 signaling pathway

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Acquired resistance to temsirolimus in human renal cell carcinoma cells is mediated by the constitutive activation of signal transduction pathways through mTORC2.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Relations between pH, oxygen partial pressure and growth in cultured cell spheroids.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Gut Bacteria Composition Drives Primary Resistance to Cancer Immunotherapy in Renal Cell Carcinoma Patients

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Lysosome-associated membrane protein 2 (LAMP-2) expression induced by miR-194-5p downregulation contributes to sunitinib resistance in human renal cell carcinoma cells

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Sphingosine kinase-1 activation causes acquired resistance against Sunitinib in renal cell carcinoma cells

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Three-dimensional cell culture models for anticancer drug screening: Worth the effort?

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Hypoxic 3D in vitro culture models reveal distinct resistance processes to TKIs in renal cancer cells

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

CRISPR/Cas9 in Genome Editing and Beyond

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Three-dimensional cell cultures: from molecular mechanisms to clinical applications

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Microfluidic 3D cell culture: from tools to tissue models

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Interaction of CCN1 with αvβ3 integrin induces P-glycoprotein and confers vinblastine resistance in renal cell carcinoma cells

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Three-dimensional spheroid model in tumor biology

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Establishment and Characterization of an In Vitro Model of Ovarian Cancer Stem-like Cells with an Enhanced Proliferative Capacity.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

The CRISPR tool kit for genome editing and beyond.

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

The use of nanoimprinted scaffolds as 3D culture models to facilitate spontaneous tumor cell migration and well-regulated spheroid formation

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Multiplexing spheroid volume, resazurin and acid phosphatase viability assays for high-throughput screening of tumour spheroids and stem cell neurospheres

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Hormonal Regulation of Patient-Derived Endometrial Cancer Stem-like Cells Generated by Three-Dimensional Culture

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

3D cell culture systems: advantages and applications

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

Corrigendum to "Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma" [Exp. Cell Res. (2017) 269-278].

1 December 2023

1 reference

https://opencitations.net/index/api/v1/references/10.3389/FONC.2022.870396

21 April 2024

Identifiers

DOI

10.3389/FONC.2022.870396

1 reference